CA3079574A1 - Drug delivery systems and methods comprising polysialic acid and/or other polymers - Google Patents

Drug delivery systems and methods comprising polysialic acid and/or other polymers Download PDF

Info

Publication number
CA3079574A1
CA3079574A1 CA3079574A CA3079574A CA3079574A1 CA 3079574 A1 CA3079574 A1 CA 3079574A1 CA 3079574 A CA3079574 A CA 3079574A CA 3079574 A CA3079574 A CA 3079574A CA 3079574 A1 CA3079574 A1 CA 3079574A1
Authority
CA
Canada
Prior art keywords
composition
acid
psa
kda
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079574A
Other languages
English (en)
French (fr)
Inventor
Maria Jose Alonso Fernandez
Desiree Teijeiro Osorio
Carmen Maria Teijeiro Valino
Ana CADETE PIRES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Publication of CA3079574A1 publication Critical patent/CA3079574A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3079574A 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers Pending CA3079574A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201731277A ES2711669A1 (es) 2017-11-02 2017-11-02 Sistemas de liberacion de farmacos de acido polisialico y metodos
ESP201731277 2017-11-02
PCT/EP2018/080050 WO2019086627A1 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers

Publications (1)

Publication Number Publication Date
CA3079574A1 true CA3079574A1 (en) 2019-05-29

Family

ID=64477081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079574A Pending CA3079574A1 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers

Country Status (8)

Country Link
US (1) US20220071917A9 (enExample)
EP (1) EP3703666A1 (enExample)
JP (2) JP7443230B2 (enExample)
AU (1) AU2018361481B2 (enExample)
CA (1) CA3079574A1 (enExample)
ES (1) ES2711669A1 (enExample)
MX (1) MX2020004639A (enExample)
WO (1) WO2019086627A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402626A (zh) * 2020-11-26 2021-02-26 中国人民解放军陆军军医大学第二附属医院 一种靶向肿瘤的生物伪装纳米递药系统及其制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
AU2020266770A1 (en) 2019-05-01 2021-10-14 Universidade De Santiago De Compostela Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules
EP3986374B1 (en) * 2019-06-21 2026-01-28 Université catholique de Louvain Lipid nanocapsules charged with incretin mimetics
WO2021163097A1 (en) 2020-02-14 2021-08-19 Chang Gung Memorial Hospital Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
CN112048002B (zh) * 2020-08-07 2021-12-10 上海维洱生物医药科技有限公司 一种靶向t细胞的酶敏感纳米体系及其制备方法和应用
CA3221371A1 (en) * 2021-06-08 2022-12-15 Cytodigm, Inc. Novel particle composition comprising sialic acid binding ligand
CN115025241B (zh) * 2022-06-22 2023-08-01 西南民族大学 靶向cd22的纳米制剂及其制备方法和应用
WO2024118638A2 (en) * 2022-11-28 2024-06-06 Colorado School Of Mines Compositions and methods for making and using polymer-coated nanocapsules for targeted pharmaceutical agent delivery
WO2025085881A1 (en) 2023-10-20 2025-04-24 Eli Lilly And Company Nanoparticles and formulations thereof for delivering therapeutic agents throughout the central nervous system
EP4652991A1 (en) 2024-05-22 2025-11-26 Universidade de Santiago de Compostela Nanoassemblies for the intracellular delivery of active principles of aminoacidic nature
CN119318719B (zh) * 2024-09-24 2025-09-05 武汉理工大学 一种靶向神经氨酸酶的载药纳米粒及其制备方法和应用
CN119318718B (zh) * 2024-09-24 2025-10-03 武汉理工大学 一种pH/神经氨酸酶双响应载药纳米粒及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
ES2385995B2 (es) 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
CA2825016C (en) 2011-01-24 2021-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
BR112014006596A2 (pt) 2011-09-21 2017-03-28 Yissum Res Dev Co nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
US9993439B2 (en) * 2012-06-20 2018-06-12 University Of Waterloo Mucoadhesive nanoparticle delivery system
PL229276B1 (pl) 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402626A (zh) * 2020-11-26 2021-02-26 中国人民解放军陆军军医大学第二附属医院 一种靶向肿瘤的生物伪装纳米递药系统及其制备方法
CN112402626B (zh) * 2020-11-26 2023-05-02 中国人民解放军陆军军医大学第二附属医院 一种靶向肿瘤的生物伪装纳米递药系统及其制备方法

Also Published As

Publication number Publication date
MX2020004639A (es) 2020-11-06
US20210228494A1 (en) 2021-07-29
EP3703666A1 (en) 2020-09-09
AU2018361481B2 (en) 2024-06-13
JP2024059777A (ja) 2024-05-01
WO2019086627A1 (en) 2019-05-09
JP7443230B2 (ja) 2024-03-05
ES2711669A1 (es) 2019-05-06
US20220071917A9 (en) 2022-03-10
JP2021516211A (ja) 2021-07-01
JP7756185B2 (ja) 2025-10-17
AU2018361481A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7756185B2 (ja) ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
Yang et al. Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy
Koren et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity
Mehra et al. Receptor-based targeting of therapeutics
Li et al. Regulation of protein corona on liposomes using albumin-binding peptide for targeted tumor therapy
JP2025041928A (ja) 薬物コンジュゲート
Nakhlband et al. Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective
US9421173B2 (en) Nano delivery systems for siRNA
Eras et al. Chemical conjugation in drug delivery systems
Wang et al. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells
JP2020121977A (ja) 疎水性薬物担体および抗菌剤としての使用のための両親媒性ペプチドナノ微粒子
Silvestre et al. Monoclonal antibodies carried in drug delivery nanosystems as a strategy for cancer treatment
US20160213788A1 (en) Active targeting antitumor drug and preparation method therefor
CN105476975B (zh) 主动靶向型抗脑肿瘤药物及其制备方法
EP3678706A1 (en) Albumin-modified nanoparticles carrying a targeting ligand
Wang et al. One-step self-assembling method to prepare dual-functional transferrin nanoparticles for antitumor drug delivery
Wöll et al. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells
Peng et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy
Wu et al. Inflammation-targeted drug delivery strategies via albumin-based systems
Alshememry et al. Using properties of tumor microenvironments for controlling local, on-demand delivery from biopolymer-based nanocarriers
CN102166190B (zh) 一种双重靶向肿瘤的紫杉醇纳米脂质体及其制备方法
CN116261469A (zh) 包含含有vhh的adc或aoc和皂苷或配体-皂苷缀合物的组合
Okada Targeted siRNA therapy using cytoplasm-responsive nanocarriers and cell-penetrating peptides
CN116322782A (zh) 单结构域抗体、皂苷和效应分子的缀合物，包含其的药物组合物，所述药物组合物的治疗用途
Iminova et al. From PEGylation to Next-Generation Polymers: Overcoming Biological Barriers–A Review

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241025

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241029

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250707

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250707